Table 3 Multivariable cox regression analysis for myelodysplastic syndromes/neoplasms patients.

From: Prognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus Classification

Variable

LFS

OS

HR (95% CI)

P value

HR (95% CI)

P value

Agea

1.031 (1.018–1.045)

<0.001

1.034 (1.019–1.049)

<0.001

Male

1.039 (0.684–1.577)

0.858

1.127 (0.732–1.736)

0.588

Ferritin > 800 (ng/mL)

1.576 (1.079–2.303)

0.019

1.560 (1.056–2.304)

0.025

LDH > 200 (ng/mL)

1.680 (1.139–2.479)

0.009

1.660 (1.109–2.485)

0.014

AMC > 75 (ng/mL)

1.037 (0.671–1.601)

0.870

1.000 (0.641–1.559)

>0.999

ALC > 2200 (ng/mL)

0.744 (0.466–1.188)

0.215

0.818 (0.508–1.318)

0.410

Presence of BM fibrosis

1.421 (0.971–2.080)

0.070

1.739 (1.172–2.580)

0.006

Transfusion dependency

1.113 (0.764–1.622)

0.575

0.927 (0.629–1.368)

0.704

Refined IPSS-M

 

<0.001

 

<0.001

 Very low/low/double negativeb

Reference

Reference

 Moderate low

1.395 (0.569–3.417)

0.467

1.385 (0.564–3.402)

0.478

 Moderate high

3.042 (1.414–6.547)

0.004

2.356 (1.065–5.210)

0.034

 High

4.799 (2.242–10.272)

<0.001

3.860 (1.788–8.334)

0.001

 Very high

11.821 (5.717–24.444)

<0.001

9.173 (4.426–19.008)

<0.001

  1. AMC absolute monocyte counts, ALC absolute lymphocyte counts, HR hazard ratio, IPSS-M molecular international prognostic scoring systems, LFS leukemia-free survival, LDH lactate dehydrogenase, MLD multilineage dysplasia, OS overall survival, SLD single-lineage dysplasia.
  2. aContinuous variable.
  3. bThis group includes the original IPSS-M very-low- and low-risk categories, as well as all cases with a normal karyotype but no detectable gene mutation.